Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (161-170 of 261) with videos related to

Pageof 27
Sort By:
Biomedicines|December 24, 2021
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAnne Linde Mak, Jenny Lee, Anne-Marieke van Dijk, et al.
JHEP Reports : Innovation in Hepatology|August 11, 2020
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN studyJamie O'Hara, Alan Finnegan, Harpal Dhillon, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Nature Reviews. Gastroenterology & Hepatology|July 17, 2024
A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
Nature Reviews. Gastroenterology & Hepatology|August 5, 2024
Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
The Journal of Clinical Investigation|January 7, 2015
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisChris J Weston, Emma L Shepherd, Lee C Claridge, et al.
Diabetologia|June 30, 2017
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory studyElina Isokuortti, You Zhou, Markku Peltonen, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Pageof 27

Showing results (161-170 of 261) with videos related to

Sort By:
Pageof 27
Biomedicines|December 24, 2021
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAnne Linde Mak, Jenny Lee, Anne-Marieke van Dijk, et al.
JHEP Reports : Innovation in Hepatology|August 11, 2020
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN studyJamie O'Hara, Alan Finnegan, Harpal Dhillon, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Nature Reviews. Gastroenterology & Hepatology|July 17, 2024
A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
Nature Reviews. Gastroenterology & Hepatology|August 5, 2024
Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosisJuan M Pericàs, Quentin M Anstee, Salvador Augustin, et al.
The Journal of Clinical Investigation|January 7, 2015
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisChris J Weston, Emma L Shepherd, Lee C Claridge, et al.
Diabetologia|June 30, 2017
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory studyElina Isokuortti, You Zhou, Markku Peltonen, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Pageof 27